Mass Spectrometry Advances in Analysis of Glioblastoma

Mass Spectrometry Reviews, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Some cancers such as glioblastoma (GBM), show minimal response to medical interventions, often only capable of mitigating tumor growth or alleviating symptoms. High metabolic activity in the microenvironment marked by immune responses and hypoxia, is a crucial factor driving progression. The many developments mass spectrometry (MS) over last decades have provided pivotal tool for studying proteins, along with their posttranslational modifications. It known that proteomic landscape GBM comprises wide range proteins involved cell proliferation, survival, migration, evasion. Combination MS imaging microscopy has potential reveal spatial molecular characteristics pathological tissue sections. Moreover, integration surgical process form techniques DESI-MS rapid evaporative ionization been shown an effective measurement metabolite profiles, providing detailed information within seconds. In immunotherapy-related research, plays indispensable role detection targeting cancer antigens which serve base antigen-specific therapies. this review, we aim provide on profile discuss recent advances clinical benefits aggressive disease.

Language: Английский

---

Lipidomics-driven drug discovery and delivery strategies in glioblastoma

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: 1871(3), P. 167637 - 167637

Published: Dec. 23, 2024

With few viable treatment options, glioblastoma (GBM) is still one of the most aggressive and deadly types brain cancer. Recent developments in lipidomics have demonstrated potential lipid metabolism as a therapeutic target GBM. The thorough examination lipids biological systems, or lipidomics, essential to comprehending changed profiles found GBM, which are linked tumor's ability grow, survive, resist treatment. use drug delivery discovery examined this study, focusing on how it may be used find new biomarkers, create multi-target directed ligands, improve systems. We also cover FDA-approved medications, clinical trials that lipid-targeted medicines, integration with other omics technologies. This study emphasizes possible tool developing more effective methods for GBM by exploring various lipid-centric techniques.

Language: Английский

---

Lentinan Regulates Glioma Cell Proliferation and Apoptosis by Activating p53 and Caspases Pathways

Pharmacognosy Magazine, Journal Year: 2024, Volume and Issue: 20(4), P. 1154 - 1166

Published: May 16, 2024

Background Gliomas are highly lethal malignancies that develop in the central nervous system. The primary treatment for gliomas involves surgical resection followed by chemoradiotherapy. However, due to infiltrative growth nature of gliomas, is often incomplete. Moreover, efficacy chemotherapeutic drugs constrained their ability cross blood–brain barrier, and currently utilized agents can lose effectiveness, particularly with prolonged administration. Lentinan, an active compound Lentinula edodes, exhibits various pharmacological activities. Purpose This study aims investigate anti-tumor effects lentinan on glioma U251 cells. Materials Methods Cell proliferation assays, cell fluorescence staining, scratch healing experiments, transwell chamber experiments were conducted assess activity Additionally, quantitative real-time polymerase chain reaction (qPCR) Western blot performed validate mechanism lentinan. Results findings revealed significantly suppressed cells, induced robust apoptosis, decreased cells’ migration invasion capabilities. Furthermore, notably influenced gene protein expression p53, Bcl-2, Cyto-c, Bax, Caspases, MMP-9 Conclusion These suggest may inhibit cells activating P53 caspase-related apoptosis pathways.

Language: Английский

---

Blood plasma lipid profile in glial tumors

Advances in molecular oncology, Journal Year: 2024, Volume and Issue: 11(3), P. 114 - 125

Published: Oct. 11, 2024

Introduction . In glial tumors, lipid metabolism becomes abnormal. Analysis of components can be an important characteristic molecular and genetic profile gliomas. Aim To determine the correlation between plasma lipidome immunohistochemical characteristics tumors to evaluate clinical significance blood spectrum analysis in preoperative assessment Materials methods Immunohistochemical measurement O-6-methylguanine-DNA-methyl transferase (MGMT), Ki-67, p53, IDH1 tumor markers was performed using corresponding antibody clones. Composition lipids assessed thin layer chromatography. Results Even at early stages gliomagenesis, significant differences cholesterol ethers, lysophosphatidylcholines, phosphatidylcholine (PC)/ lysophosphatidylcholine (LPC) ratio, neutral (NL)/phospholipids (PL) were observed. Significant correlations MGMT above-mentioned parameters found. The PC/LPC, NL/PL ratios patients from groups with higher (above 10 %) lower (below Ki-67 mitotic indexes compared healthy individuals significantly lower. Therefore, values allow indirectly assess proliferative activity gliomas which used for diagnosis these tumors. No PC/LPC found promoter methylation without it. indirect predictor criteria Conclusion It is impossible decreased epigenetic transcripts prognosis alkylating agent therapy based on metabolism.

Language: Английский

---